Unknown PHASE1 INTERVENTIONAL 3-arm NCT03896594

A Multiple Dose of HL237 in Healthy Male Subject

A Dose Block-randomized, Double-blind, Placebo Controlled, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Oral Dose of HL237 in Healthy Male Subject

Sponsor: Hanlim Pharm. Co., Ltd.

Conditions Rheumatoid Arthritis

Interventions HL237 Placebo Oral Tablet

Updated 6 times since 2019 Last updated: Mar 31, 2019 Started: Dec 24, 2018 Primary completion: Jun 30, 2019 Completion: Sep 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03896594, this PHASE1 trial focuses on Rheumatoid Arthritis and remains ongoing. Sponsored by Hanlim Pharm. Co., Ltd., it has been updated 6 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE1
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

May 2019 — Jan 2021 [monthly]

Recruiting PHASE1

First recorded

Dec 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hanlim Pharm. Co., Ltd.

Data source: Hanlim Pharm. Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea